Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P10 versus Rituxan plus CVP in advanced follicular lymphoma
NL-OMON47777Phase 3Active, not recruiting
- Sponsor
- Celltrion
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Celltrion. Primary endpoints: AUCtau, CmaxSS and 1 more. Started Oct 2014; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON47777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47777.